Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey N Miner

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|July 31, 2002
Designer glucocorticoidsJeffrey N Miner
Endocrine Reviews|April 9, 2005
The search for safer glucocorticoid receptor ligandsJonathan Rosen, Jeffrey N Miner
Expert Opinion on Investigational Drugs|January 18, 2011
Novel mitogen-activated protein kinase kinase inhibitorsMark S Chapman, Jeffrey N Miner
Current Rheumatology Reports|April 24, 2016
Urate Handling in the Human BodyDavid Hyndman, Sha Liu, Jeffrey N Miner
Joint Bone Spine|June 22, 2016
Patients with gout differ from healthy subjects in renal response to changes in serum uric acidSha Liu, Fernando Perez-Ruiz, Jeffrey N Miner
Scientific Reports|October 8, 2016
Mechanism of high affinity inhibition of the human urate transporter URAT1Philip K Tan, Traci M Ostertag, Jeffrey N Miner
Expert Opinion on Investigational Drugs|November 26, 2005
New and improved glucocorticoid receptor ligandsJeffrey N Miner, Mei Hua Hong, Andrés Negro-Vilar
Scientific Reports|April 8, 2017
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and goutPhilip K Tan, Sha Liu, Esmir Gunic, et al.
BMC Cancer|October 6, 2010
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenograftsQing Chang, Mark S Chapman, Jeffrey N Miner, et al.
Molecular Biology and Evolution|June 30, 2016
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and GoutPhilip K Tan, Jennifer E Farrar, Eric A Gaucher, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|July 31, 2002
Designer glucocorticoidsJeffrey N Miner
Endocrine Reviews|April 9, 2005
The search for safer glucocorticoid receptor ligandsJonathan Rosen, Jeffrey N Miner
Expert Opinion on Investigational Drugs|January 18, 2011
Novel mitogen-activated protein kinase kinase inhibitorsMark S Chapman, Jeffrey N Miner
Current Rheumatology Reports|April 24, 2016
Urate Handling in the Human BodyDavid Hyndman, Sha Liu, Jeffrey N Miner
Joint Bone Spine|June 22, 2016
Patients with gout differ from healthy subjects in renal response to changes in serum uric acidSha Liu, Fernando Perez-Ruiz, Jeffrey N Miner
Scientific Reports|October 8, 2016
Mechanism of high affinity inhibition of the human urate transporter URAT1Philip K Tan, Traci M Ostertag, Jeffrey N Miner
Expert Opinion on Investigational Drugs|November 26, 2005
New and improved glucocorticoid receptor ligandsJeffrey N Miner, Mei Hua Hong, Andrés Negro-Vilar
Scientific Reports|April 8, 2017
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and goutPhilip K Tan, Sha Liu, Esmir Gunic, et al.
BMC Cancer|October 6, 2010
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenograftsQing Chang, Mark S Chapman, Jeffrey N Miner, et al.
Molecular Biology and Evolution|June 30, 2016
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and GoutPhilip K Tan, Jennifer E Farrar, Eric A Gaucher, et al.
Pageof 6